Biobadaguay: Controlling the safety of treatment with Biological agents
Main Article Content
Article Sidebar
Published
2016 December 30
Paloma de Abreu
How to Cite
1.
de Abreu P. Biobadaguay: Controlling the safety of treatment with Biological agents. Rev. parag. reumatol. [Internet]. 2016 Dec. 30 [cited 2026 Oct. 26];2(2):60-1. Available from: https://www.revista.spr.org.py/index.php/spr/article/view/37
Downloads
Download data is not yet available.
Article Details
References
(1) Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic Therapy for autoinmune disesases: up to date. BMC Medicine. 2013:11-13.
(2) Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther. 2011;33:679-707.
(3) Sanmartí R, García-Rodríguez S, Álvaro-Gracia JM, Andreu JL, Balsa A, Cáliz R, et al. Actualización 2014 del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide. Reumatol Clin. 2015;11(5):279-294.
(4) Feldmann M, Maini Rn. Anti-TNF alpha therapy of rheumatoi arthritis: what have we learned?. Ann Rev immunol 2001;19:163.
(5) Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014 Mar;73(3):529-35.
(6) Carmona, Descalzo MA, Ruiz Montesinos D, Manero Ruiz FJ, Pérez-Pamplin E, Gómez Reino JJ. Safety and retention reate of off-label uses of TNF antagonist in rheumatic conditions data from the spanish registry BIOBADASER 2.0. Rheumatology (Oxford) 2011;50:85-92.
(7) Gómez Reino J, Loza E, Andreu JL, Balsa A, Batlle E, Cañete JD et.al. Consenso SER sobre la gestión de riesgo del tratamiento con terapias biológicas en pacientes con enfermedades reumáticas. Reumatol Clin. 2011;7(5):284-298.
(2) Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther. 2011;33:679-707.
(3) Sanmartí R, García-Rodríguez S, Álvaro-Gracia JM, Andreu JL, Balsa A, Cáliz R, et al. Actualización 2014 del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide. Reumatol Clin. 2015;11(5):279-294.
(4) Feldmann M, Maini Rn. Anti-TNF alpha therapy of rheumatoi arthritis: what have we learned?. Ann Rev immunol 2001;19:163.
(5) Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014 Mar;73(3):529-35.
(6) Carmona, Descalzo MA, Ruiz Montesinos D, Manero Ruiz FJ, Pérez-Pamplin E, Gómez Reino JJ. Safety and retention reate of off-label uses of TNF antagonist in rheumatic conditions data from the spanish registry BIOBADASER 2.0. Rheumatology (Oxford) 2011;50:85-92.
(7) Gómez Reino J, Loza E, Andreu JL, Balsa A, Batlle E, Cañete JD et.al. Consenso SER sobre la gestión de riesgo del tratamiento con terapias biológicas en pacientes con enfermedades reumáticas. Reumatol Clin. 2011;7(5):284-298.
Section
EDITORIAL
How to Cite
1.
de Abreu P. Biobadaguay: Controlling the safety of treatment with Biological agents. Rev. parag. reumatol. [Internet]. 2016 Dec. 30 [cited 2026 Oct. 26];2(2):60-1. Available from: https://www.revista.spr.org.py/index.php/spr/article/view/37